Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern Time

Rhea-AI Summary

Lantheus Holdings (NASDAQ: LNTH) has scheduled a conference call to announce its financial and operational results for the fourth quarter and full year of 2021. This event will take place on February 24, 2022, at 8:00 a.m. ET. Investors can join via telephone or through a live webcast on the company's website. Following the call, a replay will be accessible for 30 days. Lantheus is known for its diverse portfolio of imaging diagnostics and therapeutics, aimed at addressing serious medical conditions.

Positive

• Scheduled conference call to discuss financial performance for Q4 and full year 2021.

Negative

• None.

NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 4894137. A live webcast will also be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Director, Corporate Communications
646-975-2533
media@lantheus.com

FAQ

When is Lantheus Holdings' conference call to discuss Q4 2021 results?

The conference call is scheduled for February 24, 2022, at 8:00 a.m. ET.

How can I access the Lantheus Holdings conference call?

You can access the call by dialing 1-866-498-8390 (U.S.) or 1-678-509-7599 (international) and using passcode 4894137, or by joining through a live webcast on their website.

What are the key products offered by Lantheus Holdings?

Lantheus offers products including DEFINITY®, PYLARIFY®, TechneLite®, AZEDRA®, and RELISTOR®, focusing on imaging diagnostics and therapeutic solutions.

Where can I find the replay of the Lantheus Holdings conference call?

The replay will be available in the Investors section of the Lantheus website approximately two hours after the call and will be archived for 30 days.